1. Advances in the Understanding of Skin Cancer: Ultraviolet Radiation, Mutations, and Antisense Oligonucleotides as Anticancer Drugs.
- Author
-
Laikova KV, Oberemok VV, Krasnodubets AM, Gal'chinsky NV, Useinov RZ, Novikov IA, Temirova ZZ, Gorlov MV, Shved NA, Kumeiko VV, Makalish TP, Bessalova EY, Fomochkina II, Esin AS, Volkov ME, and Kubyshkin AV
- Subjects
- Apoptosis drug effects, Apoptosis radiation effects, Cell Transformation, Neoplastic drug effects, Cell Transformation, Neoplastic radiation effects, Humans, Antineoplastic Agents therapeutic use, Melanoma drug therapy, Melanoma metabolism, Melanoma pathology, Mutation, Oligonucleotides, Antisense therapeutic use, Skin Neoplasms drug therapy, Skin Neoplasms metabolism, Skin Neoplasms pathology, Ultraviolet Rays adverse effects
- Abstract
Skin cancer has always been and remains the leader among all tumors in terms of occurrence. One of the main factors responsible for skin cancer, natural and artificial UV radiation, causes the mutations that transform healthy cells into cancer cells. These mutations inactivate apoptosis, an event required to avoid the malignant transformation of healthy cells. Among these deadliest of cancers, melanoma and its 'younger sister', Merkel cell carcinoma, are the most lethal. The heavy toll of skin cancers stems from their rapid progression and the fact that they metastasize easily. Added to this is the difficulty in determining reliable margins when excising tumors and the lack of effective chemotherapy. Possibly the biggest problem posed by skin cancer is reliably detecting the extent to which cancer cells have spread throughout the body. The initial tumor is visible and can be removed, whereas metastases are invisible to the naked eye and much harder to eliminate. In our opinion, antisense oligonucleotides, which can be used in the form of targeted ointments, provide real hope as a treatment that will eliminate cancer cells near the tumor focus both before and after surgery., Competing Interests: The authors have no conflicts of interest.
- Published
- 2019
- Full Text
- View/download PDF